Purpose: To determine the prevalence and incidence of atrial fibrillation (AF) among older Australian women from 2000 to 2015, determine factors associated with AF, and to calculate risk of stroke at the time of AF diagnosis.
Methods: This is a retrospective analysis of 6671 women of the 1921-1926 birth cohort of the Australian Longitudinal Study on Women's Health, linked to data from hospital admissions to identify AF and National Death Index to determine date of death. Yearly prevalence and incidence proportions of AF, and stroke risk using CHADS-VA scheme, were calculated. Factors associated with AF were assessed using logistic regression.
Results: From 2000 to 2015, a total of 1827 women with AF were identified. AF prevalence increased every year as women aged from 2.71% (95% CI 1.62%-3.80%) in 2000 among women aged 74-79 years to 24.83% (95% CI = 23.23%-26.44%) in 2015 among women aged 89-94 years. The incidence proportion remained constant (between 3% and 5%) throughout the study period. Sedentary lifestyle (OR = 1.24, 95% CI = 1.04-1.49), hypertension (OR = 1.24, 95% CI = 1.09-1.42), arthritis (OR = 1.24, 95% CI = 1.09-1.41), heart attack (OR = 1.62, 95% CI = 1.18-2.24), and angina (OR = 1.39, 95% CI = 1.14-1.70) were independently associated with AF. Mean CHADS-VA score for women with AF was 3.43 (SD ± 1.23).
Conclusions: The prevalence of AF reported in Australian women is among the highest compared to previous estimations from other countries and regions. According to the findings, about one in four women over the age of 90 years had AF. These women were also at high risk of stroke. This has significant public health implications especially with changing demographics of increase in the aging population. Further research is required on understanding how women with AF are treated in Australia and their health outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.annepidem.2020.02.004 | DOI Listing |
J Endovasc Ther
April 2018
1 Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, Italy.
Purpose: To assess early and midterm outcomes of iliac branch device (IBD) implantation without an aortic stent-graft for the treatment of isolated common iliac artery aneurysm (CIAA).
Methods: From December 2006 to June 2016, 49 isolated CIAAs in 46 patients were treated solely with an IBD at 7 vascular centers. Five patients were lost to follow-up, leaving 41 male patients (mean age 72.
J Vasc Surg
September 2017
Division of Vascular Surgery, Mayo Clinic, Rochester, Minn.
Objective: The GORE EXCLUDER Iliac Branch Endoprosthesis (IBE; W. L. Gore and Associates, Flagstaff, Ariz) is an iliac branch stent graft system designed to preserve internal iliac artery perfusion during endovascular repair of aortoiliac aneurysms (AIAs) and common iliac artery (CIA) aneurysms (CIAAs).
View Article and Find Full Text PDFInt Angiol
June 2017
Department of Cardiovascular Surgery, Tokyo Medical University, Tokyo, Japan.
J Vasc Surg
June 2008
Division of Vascular Surgery, Gonda Vascular Center, Mayo Clinic, Rochester, MN 55905, USA.
Objectives: To assess expansion rate of common iliac artery aneurysms (CIAAs) and define outcomes after open repair (OR) and endovascular repair (EVAR).
Methods: Clinical data of 438 patients with 715 CIAAs treated between 1986 and 2005 were retrospectively reviewed. Size, presentations, treatments, and outcomes were recorded.
Diabetes
November 1987
Research Division, the Joslin Diabetes Center, Boston, MA 02215.
A quantitative fluid-phase radioassay for autoantibodies reacting with insulin (competitive insulin autoantibody assay, CIAA) was developed. The assay's features include 1) use of a physiologic amount of 125I-labeled insulin, 2) parallel incubations with supraphysiologic cold insulin (competitive), and 3) an incubation time of 7 days and a single-step multiple-wash polyethylene glycol separation. Mean +/- SE CIAA levels in 50 controls were 8 +/- 1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!